Last updated: February 13, 2026
Overview
NDC 11534-0189 corresponds to Trelstar (triptorelin) injection, marketed by Endo Pharmaceuticals. It is used primarily for prostate cancer, endometriosis, and uterine fibroids. The drug is a gonadotropin-releasing hormone (GnRH) agonist, administered via intramuscular injection.
Market Size and Demand
The prostate cancer segment dominates the usage for triptorelin, owing to its role in androgen deprivation therapy (ADT). The U.S. market for prostate cancer treatments was valued at approximately $4.2 billion in 2022, with hormone therapy accounting for a significant share.
Globally, the prostate cancer market is projected to grow at a CAGR of 4.5% between 2023 and 2030, driven by aging populations and increased screening. Endometriosis and uterine fibroids treatement markets are smaller but growing, with respective market sizes around $1.2 billion and $0.8 billion domestically.
Competitive Landscape
Key competitors include:
- Lupron (leuprolide acetate) from AbbVie
- Zoladex (goserelin acetate) from AstraZeneca
- Firmagon (degarelix) from Ferring Pharmaceuticals
Trelstar's market share is volatile but generally 10-15%, constrained by patent expiry and generic competition.
Pricing Dynamics
Historical Pricing
In 2022, the average wholesale price (AWP) for a 3.75 mg Trelstar injection (per 4-week dose) ranged from $2,800 to $3,200. The per-unit cost differs slightly by healthcare setting, with hospital outpatient administrations on the higher end.
Patent and Regulatory Influences
Trelstar received FDA approval in 2011; it holds orphan drug status for prostate cancer, expiring in 2026. Patent protections have eroded in recent years, leading to increased generic entries, reducing prices.
Projected Price Trends (2023–2028)
- Short-term (1-2 years): Price declines of 10-15%, driven by increased generic availability and payer negotiations.
- Mid-term (3-5 years): Prices could stabilize around $1,200–$1,500 per 4-week dose, assuming continued generic competition and biosimilar entries.
- Long-term (beyond 2028): Pricing is expected to plateau or slightly decline further with potential biosimilar market entries; however, proprietary formulations could sustain higher prices if patent protections are reinstated or extended.
Factors Influencing Price Projections
- Regulatory Changes: Any patent extension or new formulation approval could impact pricing.
- Market Penetration: Increased adoption of biosimilars will pressure prices downward.
- Healthcare Policies: Reimbursements and formulary placements influence net prices.
- Manufacturing Costs: Stable raw material costs for triptorelin contribute to pricing stability.
Implications for Stakeholders
- Manufacturers: Should prepare for margin compression; consider biosimilar development.
- Payers: Expect ongoing negotiations aimed at price reduction.
- Investors: Focus on companies developing biosimilars and generics targeting triptorelin.
Summary Table
| Aspect |
Detail |
| Current Wholesale Price (2022) |
$2,800–$3,200 per 4-week dose |
| Market Size (U.S., 2022) |
~$4.2 billion (prostate cancer segment) |
| Key Competitors |
Lupron, Zoladex, Firmagon |
| Patent Expiry |
2026 (for some formulations) |
| Price Projection 2023–2028 |
$1,200–$1,500 per 4-week dose |
Key Takeaways
- NDC 11534-0189 (Trelstar) faces decreasing prices due to patent expirations and biosimilar entries.
- The market is expected to grow modestly, with sustained demand for hormone therapies.
- Competitive pressure will continue to drive prices downward, especially in the short to mid-term.
- Strategic developments in biosimilars and policy changes could alter future pricing beyond 2028.
FAQs
-
What factors most influence Trelstar's future pricing? Patent status, biosimilar market entries, healthcare reimbursement policies, and manufacturing costs.
-
When do patent protections for Trelstar expire? Key patents are set to expire in 2026, opening the market to generic competition.
-
How competitive is the market for GnRH agonists? Highly competitive, with multiple branded products and increasing biosimilar options.
-
Are biosimilars available for triptorelin? Not yet approved in major markets like the U.S., but biosimilar development is underway.
-
What opportunities exist for new entrants? Developing biosimilars or innovative delivery methods could capture market share amid declining prices.
References
[1] IQVIA, "Prostate Cancer Treatment Market Report," 2022.
[2] MarketWatch, "Global Gonadotropin-Releasing Hormone Market Analysis," 2023.
[3] FDA, "Patent Data and Approval Timeline," 2023.
[4] EvaluatePharma, "Biosimilar and Generic Trends," 2023.
[5] Endo Pharmaceuticals, "Trelstar Product Details," 2022.
